2026-04-14T05:29:00Zhttps://recercat.cat/oai/requestoai:recercat.cat:2072/4450922025-07-29T19:12:05Zcom_2072_98col_2072_378192
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
Leleu, Xavier
Beksac, Meral
Chou, Takaaki
Dimopoulos, Meletios
Yoon, Seokbeom
Prince, H. Miles
Pour, Ludek
Shelekhova, Tatiana
Chari, Ajai
Khurana, Monica
Zhang, Jianqi
Obreja, Michaela
Qi, Ming
Oriol, Albert
Siegel, David
Universitat Autònoma de Barcelona
Daratumumab
Carfilzomib
Multiple myeloma
Weekly regimen
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
2020
Article
https://ddd.uab.cat/record/236712
urn:10.1080/10428194.2020.1832672
urn:oai:ddd.uab.cat:236712
urn:scopus_id:85094664519
urn:pmid:33112184
eng
Leukemia and Lymphoma ; 2020
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
https://creativecommons.org/licenses/by-nc-nd/4.0/
application/pdf